Vincerx Pharma, Inc. Restructuring and Related Cost, Expected Cost
Vincerx Pharma, Inc. had Restructuring and Related Cost, Expected Cost of $2.60 million as of 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes
us-gaap:RestructuringAndRelatedCostExpectedCost1 · last filed 2025-03-27
- 2024-12-31: Restructuring and Related Cost, Expected Cost $2.60M.
- 2023-12-31: Restructuring and Related Cost, Expected Cost $2.50M.
- 2022-12-31: Restructuring and Related Cost, Expected Cost $2.50M.
- 2022-09-30: Restructuring and Related Cost, Expected Cost $2.50M.
| Period end | Restructuring and Related Cost, Expected Cost |
|---|---|
| 2024-12-31 | $2.60M 10-K · filed 2025-03-27 |
| 2023-12-31 | $2.50M 10-K · filed 2024-03-29 |
| 2022-12-31 | $2.50M 10-K · filed 2023-03-28 |
| 2022-09-30 | $2.50M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.50M 10-Q · filed 2022-08-11 |